BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sacituzumab drozuntecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sacituzumab drozuntecan\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05438329-2449@assetmemo.bio
DTSTAMP:20261121T005952Z
DTSTART;VALUE=DATE:20270813
DTEND;VALUE=DATE:20270814
SUMMARY:Sacituzumab drozuntecan: Phase 1/2 readout est. (NCT05438329)
DESCRIPTION:Sacituzumab drozuntecan\, phase 1/2.\nStudy: First-in-human Stu
 dy of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors\nEstimated prima
 ry completion: 13 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-drozuntecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05438329
URL:https://assetmemo.bio/drug/sacituzumab-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953089-2449@assetmemo.bio
DTSTAMP:20261121T005952Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Sacituzumab drozuntecan: Phase 2 readout est. (NCT06953089)
DESCRIPTION:Sacituzumab drozuntecan\, phase 2.\nStudy: DB-1311 in Combinati
 on With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors\nEstimated p
 rimary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sacituzumab-drozuntecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06953089
URL:https://assetmemo.bio/drug/sacituzumab-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
